Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

80
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

21
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
21
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

561
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
561
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

42.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.9K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

896
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
896
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.

Acta clinica Croatica·2025
Same author

Dissemination of Clinical <i>Acinetobacter baumannii</i> Isolate to Hospital Environment during the COVID-19 Pandemic.

Pathogens (Basel, Switzerland)·2023
Same author

Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study.

Journal of clinical medicine·2022
Same author

Croatian genetic heritage: an updated Y-chromosome story.

Croatian medical journal·2022
Same author

CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.

Acta clinica Croatica·2022
Same author

Performance of the COVID19SEROSpeed IgM/IgG Rapid Test, an Immunochromatographic Assay for the Diagnosis of SARS-CoV-2 Infection: a Multicenter European Study.

Journal of clinical microbiology·2020

Related Experiment Video

Updated: Apr 27, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

[Chronic hepatitis B treatment].

Miro Morović, Irena Hrstić

    Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
    |July 3, 2014
    PubMed
    Summary

    Managing chronic hepatitis B aims to suppress viral replication and prevent liver disease. Current guidelines recommend entecavir, tenofovir, or pegylated interferon alfa-2a as first-line treatments.

    Area of Science:

    • Hepatology
    • Virology
    • Internal Medicine

    Background:

    • Chronic hepatitis B (HBV) management guidelines evolve, focusing on long-term viral suppression.
    • Suppression aims to prevent HBV-related cirrhosis and hepatocellular carcinoma.
    • Effective treatments are crucial for managing diverse patient populations.

    Purpose of the Study:

    • To review current clinical practice guidelines for chronic hepatitis B management.
    • To highlight first-line therapy recommendations and their efficacy.
    • To address the complexities of treating special populations with chronic HBV.

    Main Methods:

    • Review of current clinical practice guidelines for chronic hepatitis B.
    • Analysis of data from clinical trials on approved antiviral agents.

    More Related Videos

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.2K
    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    12.8K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    6.6K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.2K
    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    12.8K
  • Identification of treatment considerations for special patient groups.

    • Main Results:

    • Entecavir and tenofovir (nucleos(t)ide analogues) and pegylated interferon alfa-2a are recommended first-line therapies.
    • These agents demonstrate good efficacy in clinical trials.
    • Special populations (e.g., co-infected, immunocompromised, cirrhotic) require tailored and demanding treatment approaches.

    Conclusions:

    • Current guidelines prioritize viral suppression for chronic hepatitis B.
    • Nucleos(t)ide analogues and pegylated interferon alfa-2a are effective first-line options.
    • Managing special populations with chronic HBV presents unique challenges requiring individualized strategies.